Evidence map›Paper›PMID 39691156›Full record

Trial reportInternational journal of chronic obstructive pulmonary disease2024

Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies for Patients with COPD and Phenotypic Features of Asthma: A Pooled Post Hoc Analysis of KRONOS and ETHOS.

Shigeo Muro, Munehiro Seki, John R Hurst, David Petullo, Jonathan Marshall, Karin Bowen, Patrick F Darken, Elizabeth A Duncan, Ayman Megally, Mehul Patel

2 registry-linked trialsAbstract readClinical Trial, Phase IIIComparative StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International journal of chronic obstructive pulmonary disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02465567 phase3completednot on this map

A Randomized, Double-Blind, Multi-Center, Parallel-Group Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 on COPD Exacerbations Over a 52-Week Treatment Period in Subjects With Moderate to Very Severe COPD (Ethos)

TypeinterventionalSponsorPearl Therapeutics, Inc.Ran2015 to 2019Enrolled8,588ConditionsCOPDArmsBGF MDI 320/14.4/9.6 μg, GFF MDI 14.4/9.6 μg, BGF MDI 160/14.4/9.6 μg, BFF MDI 320/9.6 μg
NCT02497001 phase3completednot on this map

A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® as an Active Control in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

TypeinterventionalSponsorPearl Therapeutics, Inc.Ran2015 to 2018Enrolled1,902ConditionsCOPDArmsBGF MDI 320/14.4/9.6 μg, GFF MDI (PT003) 14.4/9.6 μg, BFF MDI (PT009) 320/9.6 μg, Symbicort® Turbuhaler® (TBH) Inhalation Powder
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Shigeo MuroDepartment of Respiratory Medicine, Nara Medical University, Nara, Japan.ORCID 0000-0001-7452-9191
Munehiro SekiAstraZeneca K.K., Osaka, Japan.ORCID 0000-0002-7899-9120
John R HurstUCL Respiratory, University College London, London, UK.ORCID 0000-0002-7246-6040
David PetulloAstraZeneca, Gaithersburg, MD, USA.
Jonathan MarshallAstraZeneca, Cambridge, UK.
Karin BowenAstraZeneca, Gaithersburg, MD, USA.
Patrick F DarkenAstraZeneca, Gaithersburg, MD, USA.ORCID 0000-0002-5608-2717
Elizabeth A DuncanAstraZeneca, Durham, NC, USA.
Ayman MegallyAstraZeneca, Gaithersburg, MD, USA.
Mehul PatelAstraZeneca, Cambridge, UK.ORCID 0000-0003-0435-858X

Funding

AstraZeneca
6 · The paper itself

Abstract

Background: We evaluated the inhaled corticosteroid/long-acting muscarinic antagonist/long-acting β Patients and methods: KRONOS (NCT02497001) and ETHOS (NCT02465567) enrolled patients with moderate-to-very-severe COPD, no current asthma diagnosis, and either ≥0 (KRONOS) or ≥1 (ETHOS) moderate/severe exacerbations in the prior year. This pooled post hoc analysis evaluated trough forced expiratory volume in 1 second (FEV Results: BGF improved trough FEV Conclusion: BGF was estimated to have benefits on lung function, exacerbations, and health-related quality of life versus dual therapies in patients with COPD and phenotypic features of asthma. Trial Registration: ClinicalTrials.gov NCT02497001 and NCT02465567.

Indexed as

Adrenergic beta-2 Receptor AgonistsAsthmaBronchodilator AgentsGlycopyrrolateLungMuscarinic AntagonistsPulmonary Disease, Chronic ObstructiveAdministration, InhalationAgedBudesonideBudesonide, Formoterol Fumarate Drug CombinationDisease ProgressionDrug CombinationsDrug Therapy, CombinationFemaleForced Expiratory VolumeAdrenergic beta-2 Receptor AgonistsBronchodilator AgentsBudesonideBudesonide, Formoterol Fumarate Drug CombinationDrug CombinationsFormoterol FumarateGlycopyrrolateMuscarinic Antagonistsasthmabudesonide/glycopyrronium/formoterol fumarate dihydrateCOPDexacerbationhealth-related quality of lifelung function

Identifiers

PMID39691156
PMCPMC11649577

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.